强直性脊柱炎的诊断与治疗骨科专家共识

万方数据

万方数据

万方数据

万方数据

强直性脊柱炎的诊断与治疗骨科专家共识

作者：沈彬， 裴福兴， 邱贵兴

作者单位：

刊名：

中华骨科杂志

英文刊名：Chinese Journal of Orthopaedics

年，卷(期)：2012,32(9)

1.中华医学会风湿病学分会强直性脊柱炎诊断及治疗指南[期刊论文]-中华风湿病学杂志 2010(08)

2.黄烽强直性脊柱炎 2011

3.Rudwaleit M;Braun J;Sieper J ASAS classification criteria for axial spondyloarthritis 2009(07)

4.Sieper J;Klopsch T;Richter M Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis:results of a 12-week randomised,doubleblind,controlled study 2008(03)

5.Song IH;Hermann K;Haibel H Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on

active inflammatory lesions as detected by whole-body MRI(ESTHER):a 48-week randomised controlled trial 2011(04) 6.van der Heijde D;Sieper J;Maksymowych WP2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis 2011(06)

7.Takahiko H;Hiroki M;Terufumi S Transmembrane TNFa:structure,function,and interaction with anti-TNF agents 2010

8.Maksymowych WP Update on the treatment of ankylosing spondylitis 2007(06)

9.Braun J;van den Berg R;Baraliakos X2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis 2011(06)

10.Dougados M;Braun J;Szanto S Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis:results of a randomised double-blind placebocontrolled study (SPINE) 2011(05)

11.Braun J;van der Horst-Bruinsma IE;Huang F Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis:a randomized,double-blind trial 2011(06)

12.Heldmann F;Brandt J;van der Horst-Bruinsma IE The European ankylosing spondylitis infliximab cohort(EASIC):a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab 2011(04)

13.Baraliakos X;Listing J;Fritz C Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 yearsearly clinical response predicts long-term outcome 2011(09)

14.Finckh A;Dudler J;Wermelinger F Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients 2010(04)

15.Radstake TR;Svenson M;Eijsbouts AM Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis[外文期刊] 2009(11)

16.Moots RJ;Haraoui B;Matucci-Cerinic M Differences in biologic dose-escalation,non-biologic and steroid intensification among three anti-TNF agents:evidence from clinical practice 2011(01)

17.Kim EM;Uhm WS;Bae SC Incidence of tuberculosis among korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers 2011(10)

18.Ding T;Ledingham J;Luqmani R BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies 2010(11)

19.邱贵兴;戴尅戎骨科手术学 2005

20.Howe CR;Gardner GC;Kadel NJ Perioperative medication management for the patient with rheumatoid arthritis[外文期刊] 2006(09)